Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maria Vinaixa, Miguel Angel Rodriguez, Sara Samino, Marta Díaz, Antoni Beltran, Roger Mallol, Cinta Bladé, Lourdes Ibañez, Xavier Correig, Oscar Yanes
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Q
Acceso en línea:https://doaj.org/article/a609a2e2f41b4e308298f6adaac9d0a5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!